Benefits
Long-term cognitive performance in middle-aged adults
A randomized double-blind placebo-controlled parallel study in healthy middle-aged overweight adults compared 90 mg AME (16 mg anthocyanins), 150 mg AME (27 mg anthocyanins), or placebo. Results: psychomotor speed (grooved pegboard) improved significantly, but only in the 90 mg arm (change -3.37, p=0.009); the 150 mg arm showed no cognitive benefit. Attention (number cross-out), cognitive flexibility (Stroop), serum BDNF, and vascular parameters were not affected, and blood pressure was not lowered versus placebo. Industry-funded (BioActor employees co-authored), double-blind.
Working memory and cerebral blood flow crossover trial (160 mg/day)
A crossover study in healthy overweight/obese older adults (BMI 26-31.4) compared 160 mg AME daily vs placebo. Results: spatial working memory errors (executive function) fell about 20% (p=0.006). Memory and psychomotor speed did not change. Regional cerebral blood flow decreased in one cluster in the right insular cortex, which the authors described as of unclear relevance; cerebral perfusion and peripheral vascular function were not affected. The 160 mg dose supplied 40 mg anthocyanins/day for 6 weeks. Smaller sample (n=30), industry-funded.
Acute short-term cognitive effects (7 days)
In the only published acute trial (35 healthy young adults, mean age 25, 1 week crossover, 180 mg anthocyanins/day), reaction movement time on the five-choice reaction test fell 4.8% (12 ms) versus placebo and serum BDNF rose 5.7%. Memory and executive function did not change, and arterial stiffness and retinal microvascular measures were not affected. This study had no 12-week arm. BioActor holds a US patent for cognitive performance support (specifically reaction time and attention).
BDNF (brain-derived neurotrophic factor) maintenance
Serum BDNF was measured in two trials with inconsistent results: it rose 5.7% after 1 week in young adults (PMID 38656355) but was unaffected after 24 weeks in middle-aged adults (PMID 32824483). BDNF is a neurotrophin involved in synaptic plasticity and declines with age, but a durable effect of this extract on BDNF has not been shown. The proposed route is cyanidin-3-O-galactoside reaching the CNS and modulating neurotrophic gene expression.
Cerebral perfusion enhancement (mechanism)
In the 6-week crossover trial (PMID 41499921) cerebral perfusion (transcranial Doppler) was not affected and regional cerebral blood flow decreased in one right-insula cluster of unclear relevance, so an increase in brain perfusion or oxygen uptake has not been demonstrated in people. Cyanidin-3-O-galactoside is reported to cross the blood-brain barrier, and anthocyanins can influence nitric-oxide-mediated endothelial function, but peripheral vascular measures were unchanged in all three trials.
Antioxidant + anti-inflammatory CNS effects
Anthocyanins suppress neuroinflammation and oxidative stress in CNS. Modulate pro-inflammatory signaling pathways, scavenge reactive oxygen species, enhance antioxidant defenses. Mechanism contributing to long-term neuroprotection. Aronia melanocarpa is among richest natural sources of cyanidin glycosides — concentrated form via Nero Eggert variety + standardized extraction.
Mechanism of action
Cyanidin-3-O-galactoside BBB penetration (unique among anthocyanins)
Distinguishing feature: cyanidin-3-O-galactoside (Cy3Gal) is the most BBB-permeable cyanidin glycoside — crosses blood-brain barrier directly to exert CNS effects. Mechanism: galactoside sugar provides distinct membrane transport vs more common glucosides. Aronia melanocarpa naturally contains higher Cy3Gal proportion than other berries. Brainberry® standardization enriches this molecule for cognitive applications.
BDNF gene expression maintenance
Anthocyanin metabolites in CNS modulate neurotrophic factor gene expression — particularly BDNF and TrkB pathways. Mechanism for synaptic plasticity preservation, neurogenesis support, and cognitive maintenance with aging. Distinct from acute receptor modulation.
Vascular endothelial function and NO production
Anthocyanins improve endothelial function via increased nitric oxide (NO) production. Cerebrovascular effects translate to improved cerebral perfusion and oxygen delivery. Mechanism for combined cognitive + cardiovascular benefits.
Antioxidant via direct ROS scavenging
Direct scavenging of reactive oxygen species (hydroxyl, peroxyl, superoxide radicals). Particularly effective in CNS where oxidative stress contributes to age-related cognitive decline. Catechol and phenolic structure of anthocyanins provides electron-donating antioxidant activity.
Anti-inflammatory pathway modulation
Suppresses NF-κB, COX-2, iNOS, pro-inflammatory cytokines. Mechanism for chronic inflammation reduction in CNS — relevant to cognitive aging where neuroinflammation contributes to neuronal dysfunction.
Procyanidin synergy
Aronia berries also rich in procyanidins (oligomeric flavonoid polymers) that work synergistically with anthocyanins. Combined polyphenol matrix in Brainberry® provides multi-target effects beyond single-compound activity.
Clinical trials
Randomized double-blind placebo-controlled parallel study.
101 healthy middle-aged overweight adults. Three arms: 90 mg AME (16 mg anthocyanins), 150 mg AME (27 mg anthocyanins), or placebo (maltodextrin). 24-week supplementation period. Cognitive tests: Stroop, grooved pegboard, number cross-out. Vascular function and BDNF measured.
Psychomotor speed (grooved pegboard) improved significantly in the 90 mg arm only (change -3.37, p=0.009); the 150 mg arm showed no cognitive benefit. Attention (number cross-out), cognitive flexibility (Stroop), serum BDNF, and vascular parameters were not affected, and blood pressure was not lowered versus placebo. Industry-sponsored (BioActor BV employees co-authored).
Randomized double-blind placebo-controlled crossover study (Maastricht University Medical Center, Clinical Nutrition publication). NCT05268133 completed.
30 healthy overweight or obese older adults aged 59-71 years (BMI 26-31.4). 160 mg AME daily (40 mg anthocyanins) for 6 weeks vs placebo. Brain vascular function (cerebral blood flow by ASL-MRI) and cognition were the focus.
Spatial working memory errors (executive function) fell about 20% (p=0.006). Memory and psychomotor speed did not change. Regional cerebral blood flow decreased in one right-insula cluster, described by the authors as of unclear relevance; cerebral perfusion and peripheral vascular function were not affected, so this is not a demonstrated vascular benefit. n=30, industry-sponsored crossover.
Randomized double-blind clinical trial in younger subjects (Solabia/BioActor reported study).
35 healthy young adults (mean age 25, BMI 23). One week of AME (180 mg anthocyanins/day) versus placebo, crossover. No 12-week arm.
Reaction movement time on the five-choice reaction test fell 4.8% (12 ms) versus placebo; serum BDNF rose 5.7%. Memory and executive function did not change, and arterial stiffness and retinal microvascular calibers were not affected. This was a single 1-week study; the 'sustained' 12-week improvements are not from this trial.